| UniProt ID | RL13_HUMAN | |
|---|---|---|
| UniProt AC | P26373 | |
| Protein Name | 60S ribosomal protein L13 | |
| Gene Name | RPL13 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 211 | |
| Subcellular Localization | ||
| Protein Description | ||
| Protein Sequence | MAPSRNGMVLKPHFHKDWQRRVATWFNQPARKIRRRKARQAKARRIAPRPASGPIRPIVRCPTVRYHTKVRAGRGFSLEELRVAGIHKKVARTIGISVDPRRRNKSTESLQANVQRLKEYRSKLILFPRKPSAPKKGDSSAEELKLATQLTGPVMPVRNVYKKEKARVITEEEKNFKAFASLRMARANARLFGIRAKRAKEAAEQDVEKKK | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 11 | Acetylation | SRNGMVLKPHFHKDW CCCCEEECCCCCHHH | 25.65 | 25953088 | |
| 11 | Ubiquitination | SRNGMVLKPHFHKDW CCCCEEECCCCCHHH | 25.65 | - | |
| 16 | Ubiquitination | VLKPHFHKDWQRRVA EECCCCCHHHHHHHH | 60.77 | 19608861 | |
| 16 | Acetylation | VLKPHFHKDWQRRVA EECCCCCHHHHHHHH | 60.77 | 19608861 | |
| 52 | Phosphorylation | RIAPRPASGPIRPIV HHCCCCCCCCCCCCE | 48.02 | 23403867 | |
| 74 | Methylation | HTKVRAGRGFSLEEL ECCCCCCCCCCHHHH | 41.83 | 54558869 | |
| 77 | Phosphorylation | VRAGRGFSLEELRVA CCCCCCCCHHHHHHC | 37.38 | 23927012 | |
| 82 | Methylation | GFSLEELRVAGIHKK CCCHHHHHHCCHHHH | 21.37 | 115491663 | |
| 88 | 2-Hydroxyisobutyrylation | LRVAGIHKKVARTIG HHHCCHHHHHHHHHC | 47.20 | - | |
| 88 | Ubiquitination | LRVAGIHKKVARTIG HHHCCHHHHHHHHHC | 47.20 | - | |
| 93 | Phosphorylation | IHKKVARTIGISVDP HHHHHHHHHCCCCCC | 17.51 | 20068231 | |
| 93 (in isoform 2) | Phosphorylation | - | 17.51 | 29743597 | |
| 97 | Phosphorylation | VARTIGISVDPRRRN HHHHHCCCCCCCCCC | 18.43 | 24670416 | |
| 101 | Methylation | IGISVDPRRRNKSTE HCCCCCCCCCCCCHH | 45.81 | 115491671 | |
| 105 | 2-Hydroxyisobutyrylation | VDPRRRNKSTESLQA CCCCCCCCCHHHHHH | 57.87 | - | |
| 105 | Ubiquitination | VDPRRRNKSTESLQA CCCCCCCCCHHHHHH | 57.87 | 21890473 | |
| 105 | Ubiquitination | VDPRRRNKSTESLQA CCCCCCCCCHHHHHH | 57.87 | 21890473 | |
| 105 | Acetylation | VDPRRRNKSTESLQA CCCCCCCCCHHHHHH | 57.87 | 26051181 | |
| 106 | Phosphorylation | DPRRRNKSTESLQAN CCCCCCCCHHHHHHH | 40.74 | 22167270 | |
| 107 | Phosphorylation | PRRRNKSTESLQANV CCCCCCCHHHHHHHH | 31.07 | 30266825 | |
| 109 | Phosphorylation | RRNKSTESLQANVQR CCCCCHHHHHHHHHH | 26.35 | 30266825 | |
| 122 | Phosphorylation | QRLKEYRSKLILFPR HHHHHHHHHEEEECC | 30.80 | - | |
| 123 | Ubiquitination | RLKEYRSKLILFPRK HHHHHHHHEEEECCC | 30.46 | 21890473 | |
| 123 | 2-Hydroxyisobutyrylation | RLKEYRSKLILFPRK HHHHHHHHEEEECCC | 30.46 | - | |
| 123 | Sumoylation | RLKEYRSKLILFPRK HHHHHHHHEEEECCC | 30.46 | 28112733 | |
| 123 | Sumoylation | RLKEYRSKLILFPRK HHHHHHHHEEEECCC | 30.46 | - | |
| 123 | Ubiquitination | RLKEYRSKLILFPRK HHHHHHHHEEEECCC | 30.46 | 21890473 | |
| 123 | Acetylation | RLKEYRSKLILFPRK HHHHHHHHEEEECCC | 30.46 | 25953088 | |
| 130 | Acetylation | KLILFPRKPSAPKKG HEEEECCCCCCCCCC | 43.49 | 19608861 | |
| 130 | Ubiquitination | KLILFPRKPSAPKKG HEEEECCCCCCCCCC | 43.49 | 19608861 | |
| 132 | Phosphorylation | ILFPRKPSAPKKGDS EEECCCCCCCCCCCC | 61.31 | 20860994 | |
| 136 | Acetylation | RKPSAPKKGDSSAEE CCCCCCCCCCCCHHH | 67.88 | 25953088 | |
| 136 | Ubiquitination | RKPSAPKKGDSSAEE CCCCCCCCCCCCHHH | 67.88 | 21890473 | |
| 139 | Phosphorylation | SAPKKGDSSAEELKL CCCCCCCCCHHHHHH | 39.87 | 29255136 | |
| 140 | Phosphorylation | APKKGDSSAEELKLA CCCCCCCCHHHHHHH | 44.43 | 29255136 | |
| 145 | Sumoylation | DSSAEELKLATQLTG CCCHHHHHHHHHCCC | 39.08 | 28112733 | |
| 145 | Acetylation | DSSAEELKLATQLTG CCCHHHHHHHHHCCC | 39.08 | 25953088 | |
| 145 | Ubiquitination | DSSAEELKLATQLTG CCCHHHHHHHHHCCC | 39.08 | 21890473 | |
| 148 | Phosphorylation | AEELKLATQLTGPVM HHHHHHHHHCCCCCC | 34.25 | 30108239 | |
| 151 | Phosphorylation | LKLATQLTGPVMPVR HHHHHHCCCCCCCCC | 29.62 | 30108239 | |
| 155 | Sulfoxidation | TQLTGPVMPVRNVYK HHCCCCCCCCCCCCH | 2.60 | 28465586 | |
| 158 | Acetylation | TGPVMPVRNVYKKEK CCCCCCCCCCCHHHH | 22.49 | 19608861 | |
| 158 | Ubiquitination | TGPVMPVRNVYKKEK CCCCCCCCCCCHHHH | 22.49 | 19608861 | |
| 162 | Sumoylation | MPVRNVYKKEKARVI CCCCCCCHHHHCEEE | 50.61 | - | |
| 170 | Phosphorylation | KEKARVITEEEKNFK HHHCEEECHHHHHHH | 34.19 | - | |
| 174 | Ubiquitination | RVITEEEKNFKAFAS EEECHHHHHHHHHHH | 71.60 | 21890473 | |
| 174 | Sumoylation | RVITEEEKNFKAFAS EEECHHHHHHHHHHH | 71.60 | 25114211 | |
| 174 | Acetylation | RVITEEEKNFKAFAS EEECHHHHHHHHHHH | 71.60 | 23749302 | |
| 174 | Ubiquitination | RVITEEEKNFKAFAS EEECHHHHHHHHHHH | 71.60 | 21890473 | |
| 177 | Ubiquitination | TEEEKNFKAFASLRM CHHHHHHHHHHHHHH | 52.57 | 21890473 | |
| 177 | Ubiquitination | TEEEKNFKAFASLRM CHHHHHHHHHHHHHH | 52.57 | 21890473 | |
| 177 | Methylation | TEEEKNFKAFASLRM CHHHHHHHHHHHHHH | 52.57 | 19608861 | |
| 177 | Acetylation | TEEEKNFKAFASLRM CHHHHHHHHHHHHHH | 52.57 | 19608861 | |
| 177 | Sumoylation | TEEEKNFKAFASLRM CHHHHHHHHHHHHHH | 52.57 | - | |
| 177 | Sumoylation | TEEEKNFKAFASLRM CHHHHHHHHHHHHHH | 52.57 | 28112733 | |
| 181 | Phosphorylation | KNFKAFASLRMARAN HHHHHHHHHHHHHHH | 15.28 | 22199227 | |
| 200 | Acetylation | GIRAKRAKEAAEQDV CHHHHHHHHHHHHHH | 52.50 | 26051181 | |
| 200 | Ubiquitination | GIRAKRAKEAAEQDV CHHHHHHHHHHHHHH | 52.50 | 21890473 | |
| 200 | Methylation | GIRAKRAKEAAEQDV CHHHHHHHHHHHHHH | 52.50 | 21679131 | |
| 210 | Acetylation | AEQDVEKKK------ HHHHHHHCC------ | 50.65 | 23749302 | |
| 211 | Acetylation | EQDVEKKK------- HHHHHHCC------- | 76.32 | 12435169 |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of RL13_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of RL13_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Acetylation | |
| Reference | PubMed |
| "Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-16 AND LYS-177, AND MASSSPECTROMETRY. | |
| Phosphorylation | |
| Reference | PubMed |
| "Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-106, AND MASSSPECTROMETRY. | |
| "Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77 AND SER-106, AND MASSSPECTROMETRY. | |
| "Evaluation of the low-specificity protease elastase for large-scalephosphoproteome analysis."; Wang B., Malik R., Nigg E.A., Korner R.; Anal. Chem. 80:9526-9533(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-106, AND MASSSPECTROMETRY. | |